Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



MS sufferer gifted $1000 worth of medicinal cannabis

Peter, Ashleigh and Riley Brown with Ashleigh's parents, who paid for Riley's Sativex medication

A multiple sclerosis sufferer has been gifted an extra month of medicinal cannabis treatment thanks to the generosity of a young couple from central Otago.

Peter and Ashleigh Brown spent more than a year battling for access to Sativex for their son, Riley, who was born with the rare congenital disorder Zellweger syndrome. Tragically, Riley died in April on the very day he was supposed to begin treatment, meaning they never found out whether it could have relieved his suffering.

Mother Ashleigh says it was a heart-breaking experience.

"It was just so gutting that 14 months of hard work trying to get it for Riley, and then the day he was going to start it was the day that we lost him."

Since then they've had the unused medicine sitting in their fridge at home while they've pondered what to do with it. They agreed it didn't seem right to let it go to waste.

"We could either take it back to the pharmacy for them to destroy it, but $1000 is a lot of money to just put down the drain, or we could pass it on to someone who also has a prescription for it," says Ms Brown.

That lucky person turned out to be Dr Huhana Hickey, whom they met through charity group MC Awareness, which advocates for people struggling to get access to medicinal cannabis.

Dr Hickey suffers from constant pain, and has been in a wheelchair for 20 years. She's one of the few Kiwis who have been granted access to Sativex, but that was only the beginning of a steep uphill battle.

"Getting the approval was easy," she says. "The difficulty of getting access is how much it costs. It's $1200 each month, and that's an awful lot of money just for the average New Zealander."

Dr Hickey is grateful for the Browns' generosity.

"I'm coming up now to a point where I can't afford to buy any more," she says. "I've been buying for four months; that's $4800 that I've forked out in medicine. So this is just going to make a huge difference."

When asked if she'd consider accessing cannabis on the black market as many other chronic pain sufferers do, Dr Hickey replies that she'd rather not.

"I've thought about it, but I have my job. I would lose my credibility if I turned around and went down the illegal road."

But she won't rule it out completely.

"It's tempting. Maybe when I can't afford it and get to that point I might do that, but for as long as I can I want to stay legal."

Sativex is the only medicinal cannabis product currently approved for use in New Zealand. It's not funded by Pharmac, which means those who get a prescription have to cover the cost themselves.

Pharmac has ruled out funding the drug for now, as it says there's not yet enough clinical evidence to back government investment.

Story Source: The above story is based on materials provided by NEWSHUB
Note: Materials may be edited for content and length


Go to Newer News Go to Older News